GLP-1 Peptide Atlas, by Delfa

UnknownPhase 1, PHASE2

Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus

A Randomized Clinical Trial Comparing Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes

Lead sponsor

Ministry of Health, Saudi Arabia

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

120

estimated

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change (HbA1c, change)

Identifiers

Registered as

NCT IDNCT06057077

Org study IDAmr Ahmed, Maher M.Akl

Timeline

Milestones

Study first posted2023-09-28actual

Last update posted2023-09-28actual

Study start2024-01-01estimated

Primary completion2024-12-31estimated

Study completion2024-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age35 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

early diagnosed type 1 diabetic patients were diagnosed in the last 6 months age of two groups: from 18-35 years basal-bolus insulin patients

Exclusion criteria

no oral hypoglycemic drugs no pregnancy no hypoglycemic drugs or immunosuppressant no history of diabetic ketoacidosis

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Weight & body composition

1 endpoint

Secondary/protocol endpoint

the change in weight after follow up of one year

Time frame:one year

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint/low confidence

change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow up

Time frame:Time Frame: one year

HbA1c, change

change from baseline, improvement

componentsHbA1c, change

LOINC 4548-4

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.
Advanced pharmaceutical bulletin2024 Jul (month)PMID39206389doi:10.34172/apb.2024.040via clinicaltrials gov reference derived + pubmed nct search
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Molecular cancer therapeutics2016 Jun (month)PMID27048952doi:10.1158/1535-7163.MCT-15-0815via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.